Found 9 clinical trials
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
- 0 views
- 25 Jun, 2025
- 4 locations
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
participants with relapsed/refractory multiple myeloma will be enrolled at approximately 25 sites across the worldIn Arm A participants will receive one of two doses of ABBV-383 as an SC injection and (IV
- 0 views
- 03 Jul, 2025
- 15 locations
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop …
- 0 views
- 06 May, 2025
- 1 location
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.The
- 0 views
- 03 Jul, 2025
- 1 location
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready …
- 0 views
- 31 Jul, 2025
- 8 locations
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- 0 views
- 03 Jul, 2025
- 16 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the
- 0 views
- 03 Jul, 2025
- 26 locations
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
This is a first-in-human (FIH) Phase 1/Phase 2 study for evaluating SAR445514 in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light chain
- 0 views
- 03 Dec, 2024
- 14 locations
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to …
- 0 views
- 03 Jul, 2025
- 111 locations